Zacks Industry Outlook Highlights Envista, BioLife Solutions, InfuSystems and MariMed
Despite industry headwinds, Envista, BioLife Solutions, InfuSystems and MariMed are leveraging innovation and strategy for growth.
4 Medical Product Stocks to Watch From a Challenging Industry
The Zacks Medical products industry sees steady demand, but tariffs & policy headwinds keep growth under pressure in 2025. NVST, BLFS, INFU and MRMD reflect the favorable fundamentals.
BioLife Solutions ( BLFS ) Upgraded to Strong Buy: Here's Why
BioLife Solutions (BLFS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Predict a 39.92% Upside in BioLife Solutions ( BLFS ) : Here's What You Should Know
The mean of analysts' price targets for BioLife Solutions (BLFS) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
BioLife Solutions, Inc. ( BLFS ) Reports Break-Even Earnings for Q2
BioLife Solutions (BLFS) delivered earnings and revenue surprises of +100.00% and +6.98%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
MariMed Inc. ( MRMD ) Reports Break-Even Earnings for Q2
MariMed Inc. (MRMD) delivered earnings and revenue surprises of +100.00% and -2.91%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts
ENSG adds Idaho and Texas facilities to its skilled nursing facility and real estate portfolios and earns an opportunity to boost revenues by catering to growing patient volumes.
Encompass Health Plans a 50-Bed Unit to Better Serve North Las Vegas
EHC unveils plans for a 50-bed rehabilitation hospital in North Las Vegas, bringing improved health outcomes to the region's residents and further solidifying its Nevada footprint.
How Much Upside is Left in BioLife Solutions ( BLFS ) ? Wall Street Analysts Think 41.72%
The average of price targets set by Wall Street analysts indicates a potential upside of 41.7% in BioLife Solutions (BLFS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
EHC Opens Rehabilitation Unit in Fort Myers, Boosts Florida Footprint
Encompass Health inaugurates the Rehabilitation Hospital of Fort Myers in partnership with Lee Health to provide high-quality rehabilitation services across Florida.
Can BioLife Solutions ( BLFS ) Climb 30.68% to Reach the Level Wall Street Analysts Expect?
The consensus price target hints at a 30.7% upside potential for BioLife Solutions (BLFS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioLife Solutions, Inc. ( BLFS ) Q1 Earnings and Revenues Beat Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 233.33% and 5.28%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Green Thumb Industries Inc. ( GTBIF ) Q1 Earnings and Revenues Miss Estimates
Green Thumb Industries Inc. (GTBIF) delivered earnings and revenue surprises of -20% and 2.01%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ResMed ( RMD ) Q3 Earnings and Revenues Surpass Estimates
ResMed (RMD) delivered earnings and revenue surprises of 0.42% and 0.53%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Insulet ( PODD ) : Can Its 7.2% Jump Turn into More Strength?
Insulet (PODD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, WLDN, NXT, NVO and ...
5 Low-Leverage Stocks to Buy Amid Volatile Market Sentiment
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, BHLB, NVDA, GBX and EZPW.
BioLife Solutions, Inc. ( BLFS ) Reports Q4 Loss, Tops Revenue Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 83.33% and 6.29%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions, Inc. ( BLFS ) Hit a 52 Week High, Can the Run Continue?
BioLife Solutions (BLFS) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Strong Segmental Performance to Drive Stryker's Q4 Earnings?
SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Is BioLife Solutions ( BLFS ) Stock Outpacing Its Medical Peers This Year?
Here is how BioLife Solutions, Inc. (BLFS) and Ginkgo Bioworks Holdings, Inc. (DNA) have performed compared to their sector so far this year.
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% - Century Therapeutics ( NASDAQ:IPSC )
Shares of Century Therapeutics Inc IPSC zoomed by 20.74% to $1.63 per share on Wednesday, which is the highest price move in nearly a month since Oct. 1. The shares also rose the most in over 11 months since Dec. 6, 2023, in a single day.
BioLife Solutions, Inc. ( BLFS ) Reports Q3 Loss, Tops Revenue Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 77.78% and 21.98%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation ( CGC ) Reports Q2 Loss, Misses Revenue Estimates
Canopy Growth (CGC) delivered earnings and revenue surprises of -150% and 1.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging BioLife Solutions ( BLFS ) This Year?
Here is how BioLife Solutions, Inc. (BLFS) and Eli Lilly (LLY) have performed compared to their sector so far this year.
Biopreservation Market to Reach Market Valuation of USD 20.54 Billion by 2031 | SkyQuest Technology
Westford, USA, Oct. 16, 2024 ( GLOBE NEWSWIRE ) -- SkyQuest projects that the Global Biopreservation Market will reach a value of USD 20.54 Billion by 2031, with a CAGR of 28.30% during the forecast period ( 2024-2031 ) .
Are Medical Stocks Lagging Eli Lilly ( LLY ) This Year?
Here is how Eli Lilly (LLY) and BioLife Solutions, Inc. (BLFS) have performed compared to their sector so far this year.
Are Medical Stocks Lagging BioLife Solutions ( BLFS ) This Year?
Here is how BioLife Solutions, Inc. (BLFS) and Sensus Healthcare, Inc. (SRTS) have performed compared to their sector so far this year.
BioLife Solutions, Inc. ( BLFS ) Reports Q2 Loss, Tops Revenue Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 57.14% and 19.03%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Envista ( NVST ) Q2 Earnings and Revenues Lag Estimates
Envista (NVST) delivered earnings and revenue surprises of -59.26% and 2.30%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Owens & Minor ( OMI ) Q2 Earnings and Revenues Surpass Estimates
Owens & Minor (OMI) delivered earnings and revenue surprises of 9.09% and 0.79%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
ResMed ( RMD ) Beats Q4 Earnings and Revenue Estimates
ResMed (RMD) delivered earnings and revenue surprises of 2.46% and 0.73%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
What Makes BioLife Solutions ( BLFS ) a Good Fit for 'Trend Investing'
BioLife Solutions (BLFS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
BioLife ( BLFS ) Progresses in Cell & Gene Therapy With CryoCase
BioLife's (BLFS) latest product, CryoCase, is compatible with various downstream processing systems, including its own Signata CT-5.
BioLife Solutions ( NASDAQ:BLFS ) Upgraded by StockNews.com to Sell
BioLife Solutions ( NASDAQ:BLFS - Get Free Report ) was upgraded by stock analysts at StockNews.com to a "sell" rating in a note issued to investors on Friday. Separately, Jefferies Financial Group began coverage on BioLife Solutions in a report on Thursday, April 4th.
BioLife Solutions, Inc. ( BLFS ) Reports Q1 Loss, Tops Revenue Estimates
BioLife Solutions (BLFS) delivered earnings and revenue surprises of 26.92% and 8.28%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
BioLife Solutions Reports First Quarter 2024 Financial Results
GAAP gross margin of 38% and net loss of $10.2 million Non-GAAP adjusted gross margin expands from 40% to 53% and adjusted EBITDA of $3.6 million or 13% ex-GCI freezers
ICU Medical ( ICUI ) Q1 Earnings and Revenues Surpass Estimates
ICU Medical (ICUI) delivered earnings and revenue surprises of 14.29% and 2.44%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
The Benchmark Company Announces Upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference
NEW YORK, May 06, 2024 ( GLOBE NEWSWIRE ) -- The Benchmark Company is pleased to announce our upcoming Healthcare House Call VIRTUAL One-on-One Investor Conference happening on Tuesday & Wednesday, May 21st - 22nd, 2024.
BioLife Solutions, Inc. ( BLFS ) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
BioLife Solutions (BLFS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Boston Scientific Q1 Earnings and Revenues Top Estimates - Boston Scientific ( NYSE:BSX ) , BioLife Solns ( NASDAQ:BLFS )
Boston Scientific BSX came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.51 per share. This compares to earnings of $0.47 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of ...
Boston Scientific ( BSX ) Q1 Earnings and Revenues Top Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of 9.80% and 4.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Meta Platforms, Pure Storage And 2 Other Stocks Insiders Are Selling - Meta Platforms ( NASDAQ:META ) , BioLife Solns ( NASDAQ:BLFS )
The Nasdaq 100 closed lower by around 100 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders sell shares, it could be a preplanned sale, or could indicate their concern in the company's prospects or that they view the stock as being overpriced.
BioLife Solutions Announces the Divestiture of its Stirling Freezer Business
BOTHELL, Wash., April 18, 2024 /PRNewswire/ -- BioLife Solutions, Inc. ( NASDAQ: BLFS ) ( "BioLife" or the "Company" ) , a leading developer and supplier of bioproduction products and services for the cell and gene therapy ( "CGT" ) and the broader biopharma markets, today announced that it has ...
Global Tissue Banking Market to Exhibit Growth at a Considerable CAGR of ~6% by 2030, Assesses DelveInsight
The tissue banking market is experiencing a surge in demand due to several factors: the growing prevalence and occurrence of chronic illnesses, the expanding elderly population susceptible to such ailments, and the potential breakthroughs in treating cancers, blood disorders, immune conditions, ...
BioLife Solutions Announces Preliminary Fourth Quarter and Full Year 2023 Unaudited Revenue
BOTHELL, Wash., Jan. 8, 2024 /PRNewswire/ -- BioLife Solutions, Inc. ( NASDAQ: BLFS ) ( "BioLife" or the "Company" ) , a leading developer and supplier of bioproduction products and services for the cell and gene therapy ( CGT ) and the broader biopharma markets, today announced 2023 fourth ...
BioLife Solutions Reports Third Quarter 2023 Financial Results
BOTHELL, Wash., Nov. 9, 2023 /PRNewswire/ -- ( Nasdaq: BLFS ) ( "BioLife" or the "Company" ) , a leading supplier of biopreservation media and other cell processing tools and biostorage services for the cell and gene therapy ( CGT ) and broader biopharma markets, today announced financial ...
Over $1M Bet On Carnival? Check Out These 3 Stocks Insiders Are Buying - BioLife Solns ( NASDAQ:BLFS ) , Amrep ( NYSE:AXR )
Although U.S. stocks closed mixed on Monday, there were a few notable insider trades. When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.
BioLife Solutions Announces Leadership Transitions & Preliminary Third Quarter Revenue with Updated Outlook for 2023
Preliminary Q3 revenue of $33.3 million and expect 2023 revenue at the low end of the previously announced guidance range
New Strong Sell Stocks for October 9th
BLFS, BWMN and FTEK have been added to the Zacks Rank #5 (Strong Sell) List on October 9, 2023.
